Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633817 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL30510296 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL29398902 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL29400893 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL120592 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL118926 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL30688517 | 0.95 | ITGB3 (0.44) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL25182226 | 0.93 | ITGB3 (0.42) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL25182320 | 0.93 | ITGB3 (0.42) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL25356271 | 0.93 | PPARG (0.43) | ITGB3ITGA2BFABP5FABP7PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285592-A | Preparation method of cyclohexalipopeptides natural product Cladoamide B | 哈尔滨工业大学（深圳） | 2023-12-26 | — | — | CN | claimed |
| CN-117285602-A | Preparation method of depsipeptide natural product Isaridin A | 哈尔滨工业大学（深圳） | 2023-12-26 | — | — | CN | claimed |
| CN-115626951-A | CladoamideA preparation method | 哈尔滨工业大学（深圳） | 2023-01-20 | — | — | CN | claimed |
| CN-115626951-B | Preparation method of Cladoamide A | 哈尔滨工业大学（深圳） | 2026-03-24 | — | — | CN | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| US-5783170-A | Peptide-metal chelate conjugates | DIATIDE, INC. (US) | 1998-07-21 | — | — | US | disclosed |
| EP-0850238-A1 | COMBINATORIAL 1,4-BENZODIAZEPIN-2,5-DIONE LIBRARY | PHARMACOPEIA, INC. (US) | 1998-07-01 | — | — | EP | disclosed |
| EP-0759786-A1 | SOMATOSTATIN BINDING PEPTIDE-METAL CHELATE CONJUGATES | DIATECH, INC. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1997001560-A1 | COMBINATORIAL 1,4-BENZODIAZEPIN-2,5-DIONE LIBRARY | PHARMACOPEIA, INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5508437-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1995031221-A1 | SOMATOSTATIN BINDING PEPTIDE-METAL CHELATE CONJUGATES | DIATECH, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| US-5296608-A | Intermediates for analogs of tyrosine sulfate or tyrosine phosphate containing peptides | HOFFMAN-LA ROCHE INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-5182263-A | Appetite suppressants | HOFFMANN-LA ROCHE INC. (US) | 1993-01-26 | — | — | US | disclosed |
| EP-0339549-A2 | Tyr-peptide analogs | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | ITGB3 4817/4885ITGA2B 4589/4885FABP5 4703/4885 |
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | KRAS, G3BP1, G3BP2 | ITGB3 4367/4885ITGA2B 3400/4885FABP5 1054/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | ITGB3 4288/4885ITGA2B 4447/4885FABP5 2565/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | ITGB3 4650/4885ITGA2B 4792/4885FABP5 4026/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ITGB3 4288/4885ITGA2B 4447/4885FABP5 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.